DEC1 Polyclonal antibody

DEC1 Polyclonal Antibody for IHC,ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human and More (1)

Applications

WB, IHC,ELISA

Conjugate

Unconjugated

Cat no : 25021-1-AP

Synonyms

CTS9, DEC1, DELEC1, deleted in esophageal cancer 1



Tested Applications

Positive IHC detected inhuman prostate cancer tissue, human testis tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Immunohistochemistry (IHC)IHC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Published Applications

WBSee 1 publications below

Product Information

The immunogen of 25021-1-AP is DEC1 Fusion Protein expressed in E. coli.

Tested Reactivity human
Cited Reactivityrat
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen DEC1 fusion protein Ag20192
Full Name deleted in esophageal cancer 1
Calculated Molecular Weight 70 aa, 8 kDa
GenBank Accession NumberBC153139
Gene Symbol DEC1
Gene ID (NCBI) 50514
RRIDAB_2879851
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

DEC1 (Deleted in esophageal cancer 1), also named as CTS9 (Candidate tumor suppressor CTS9),is a tumor suppressor protein. It is expressed in many tissues, with highest expression in prostate and testis. This gene is different to another DEC1 protein (Differentially expressed in chondrocytes protein 1, BHLHE40).

Protocols

Product Specific Protocols
IHC protocol for DEC1 antibody 25021-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
ratWB

FASEB J

Persistent myopathy despite release of partial obstruction: in vivo reversal of dysfunction and transcriptional responses using rapamycin.

Authors - Annette Schröder